CANADIAN EXPERT CONSENSUS ON USE OF HALOBETASOL PROPIONATE/TAZAROTENE LOTION FOR PLAQUE PSORIASIS

被引：0
|
作者：
Guenther, L. [1 ]
Prajapati, V [2 ,3 ]
Vender, R. [4 ]
Albrecht, L. [5 ]
Maari, C. [6 ]
Yanofsky, H. [7 ]
Gaudet, V [8 ]
Turchin, I [9 ]
机构：
[1] Guenther Dermatol Res Ctr, London, ON, Canada
[2] Univ Calgary, Dermatol Res Inst, Skin Hlth Wellness Ctr, Calgary, AB, Canada
[3] Prob Med Res, Calgary, AB, Canada
[4] Dermatrials Res Inc, Hamilton, ON, Canada
[5] Enverus Med Res, Surrey, BC, Canada
[6] Innovaderm Res, Montreal, PQ, Canada
[7] Howard Yanofsky Med Serv Inc, Montreal, PQ, Canada
[8] Canada Inc, Bausch Hlth, Laval, PQ, Canada
[9] Brunswick Dermatol Ctr, Fredericton, NB, Canada
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA56
引用
收藏
页码：S407 / S407
页数：1
相关论文
共 50 条
  • [1] Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis
    Guenther, Lyn
    Turchin, Irina
    Vender, Ron
    Albrecht, Lorne E.
    Maari, Catherine
    Yanofsky, Howard
    Prajapati, Vimal H.
    DERMATOLOGY AND THERAPY, 2024, 14 (07) : 1917 - 1928
  • [2] Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
    Reddy, Vidhatha
    Myers, Bridget
    Yang, Eric J.
    Bhutani, Tina
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2020, 13 : 391 - 398
  • [3] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Brownstone, Nicholas D.
    Bhutani, Tina
    Koo, John
    CURRENT DERMATOLOGY REPORTS, 2021, 10 (01) : 21 - 25
  • [4] Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis
    Nicholas D. Brownstone
    Tina Bhutani
    John Koo
    Current Dermatology Reports, 2021, 10 : 21 - 25
  • [5] Efficacy of halobetasol and tazarotene lotion for plaque psoriasis utilizing IGAxBSA measurements
    Blauvelt, Andrew
    Green, Lawrence J.
    Bagel, Jerry
    Lin, Tina
    Martin, Gina
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB201 - AB201
  • [6] Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2023, 27 (03) : 293 - 294
  • [7] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [8] Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis
    Kircik, Leon
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (02) : 50 - 53
  • [9] Y Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color
    Alexis, Andrew F.
    Desai, Seemal R.
    Han, George
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (07) : 735 - 744
  • [10] Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion
    Desai, Seemal R.
    Alexis, Andrew F.
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (10) : 1000 - 1004
12345